Frontier Capital Management CO LLC Biomarin Pharmaceutical Inc Transaction History

Frontier Capital Management CO LLC

$9.96 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $2.24 Million - $2.77 Million	30,083 Added 8.45%	386,213 $31.8 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $7.23 Million - $8.55 Million	-86,326 Reduced 19.51%	356,130 $31.1 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $838,648 - $1.08 Million	11,003 Added 2.55%	442,456 $42.7 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $7.3 Million - $8.11 Million	-85,858 Reduced 16.6%	431,453 $38.2 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $7.04 Million - $8.15 Million	-81,210 Reduced 13.57%	517,311 $44.8 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $1.21 Million - $1.62 Million	-13,828 Reduced 2.26%	598,521 $58.2 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $11.9 Million - $16 Million	-147,191 Reduced 19.38%	612,349 $63.4 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $12.3 Million - $14.5 Million	149,238 Added 24.45%	759,540 $64.4 Million
Q2 2022 Jul 20, 2022	BUY	$71.48 - $86.85 $14.6 Million - $17.8 Million	204,399 Added 50.36%	610,302 $50.6 Million
Q1 2022 Apr 14, 2022	SELL	$74.28 - $92.69 $2.89 Million - $3.6 Million	-38,875 Reduced 8.74%	405,903 $31.3 Million
Q4 2021 Jan 19, 2022	SELL	$71.72 - $91.47 $3.78 Million - $4.83 Million	-52,752 Reduced 10.6%	444,778 $39.3 Million
Q3 2021 Oct 19, 2021	SELL	$74.77 - $85.47 $8.13 Million - $9.29 Million	-108,678 Reduced 17.93%	497,530 $38.5 Million
Q2 2021 Aug 09, 2021	BUY	$75.51 - $84.79 $1.91 Million - $2.14 Million	25,296 Added 4.35%	606,208 $50.6 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $7.18 Million - $8.71 Million	-96,069 Reduced 14.19%	580,912 $43.9 Million
Q4 2020 Jan 19, 2021	SELL	$72.61 - $90.2 $20.5 Million - $25.4 Million	-282,001 Reduced 29.41%	676,981 $59.4 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $14.7 Million - $26.9 Million	204,917 Added 27.17%	958,982 $73 Million
Q2 2020 Jul 17, 2020	SELL	$79.55 - $124.22 $18.2 Million - $28.4 Million	-228,531 Reduced 23.26%	754,065 $93 Million
Q1 2020 Apr 16, 2020	SELL	$71.37 - $96.85 $8.92 Million - $12.1 Million	-124,965 Reduced 11.28%	982,596 $83 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $22.8 Million - $30.6 Million	354,659 Added 47.11%	1,107,561 $93.6 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $2.54 Million - $3.21 Million	-37,724 Reduced 4.77%	752,902 $50.7 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $23.8 Million - $27.8 Million	-296,385 Reduced 27.27%	790,626 $67.7 Million
Q1 2019 May 07, 2019	SELL	$84.2 - $98.62 $22.7 Million - $26.6 Million	-269,583 Reduced 19.87%	1,087,011 $96.6 Million
Q4 2018 Jan 25, 2019	SELL	$80.14 - $106.07 $2.24 Million - $2.96 Million	-27,901 Reduced 2.02%	1,356,594 $116 Million
Q3 2018 Oct 30, 2018	BUY	$93.92 - $105.72 $16.3 Million - $18.4 Million	174,023 Added 14.38%	1,384,495 $134 Million
Q2 2018 Aug 03, 2018	BUY	$76.01 - $99.03 $27.6 Million - $35.9 Million	362,531 Added 42.75%	1,210,472 $114 Million
Q1 2018 Apr 30, 2018	BUY	$77.67 - $92.63 $1.5 Million - $1.79 Million	19,275 Added 2.33%	847,941 $68.7 Million
Q4 2017 Jan 18, 2018	BUY	$80.76 - $95.13 $5.82 Million - $6.86 Million	72,120 Added 9.53%	828,666 $73.9 Million
Q3 2017 Oct 31, 2017	BUY	$80.6 - $94.95 $61 Million - $71.8 Million	756,546	756,546 $70.4 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.44 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.22 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.2 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$881 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$666 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frontier Capital Management CO LLC with notifications on news.

Account